Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 22, 2017
Feasibility of atlas-based active bone marrow sparing intensity modulated radiation therapy for cervical cancerNan Li, Sonal S Noticewala, Casey W Williamson, et al.
Plos One|October 15, 2016
Early Detection of Malignant Transformation in Resected WHO II Low-Grade Glioma Using Diffusion Tensor-Derived Quantitative MeasuresMartin T Freitag, Klaus H Maier-Hein, Francisczek Binczyk, et al.
Neuro-Oncology|October 29, 2024
Imaging PD-L1 in the brain-Journey from the lab to the clinicDawoud Dar, Magdalena Rodak, Chiara Da Pieve, et al.
Physics and Imaging in Radiation Oncology|September 22, 2025
The prognostic value of baseline 18FDG - Positron Emission Tomography - Computed Tomography in cervical cancer patients treated with definitive chemoradiotherapy - External multicentre validation modelEmilia Staniewska, Magdalena Stankiewicz, Ewa Burchardt, et al.
Frontiers in Oncology|August 15, 2020
Comparison of Hematologic Toxicity and Bone Marrow Compensatory Response in Head and Neck vs. Cervical Cancer Patients Undergoing ChemoradiotherapyLucas K Vitzthum, Elena S Heide, Helen Park, et al.
Neuro-Oncology|March 13, 2015
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE studyL Burt Nabors, Karen L Fink, Tom Mikkelsen, et al.
Folia Histochemica Et Cytobiologica|January 5, 2017
Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapyMichal Jarzab, Monika Kowal, Wieslaw Bal, et al.
International Journal of Radiation Oncology, Biology, Physics|August 22, 2021
Positron Emission Tomography-Guided Bone Marrow-Sparing Radiation Therapy for Locoregionally Advanced Cervix Cancer: Final Results From the INTERTECC Phase II/III TrialCasey W Williamson, Igor Sirák, Ronghui Xu, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 20, 2021
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001Christian Marth, Rafal Tarnawski, Alexandra Tyulyandina, et al.
NPJ Breast Cancer|June 26, 2026
Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse eventsHope S Rugo, David W Cescon, Peter Schmid, et al.
Pageof 4